[{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "619 949 3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 593, "companyOfficers": [{"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 68, "title": "President & Chairman", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 10500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 121352, "exercisedValue": 0, "unexercisedValue": 15073756}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 274617, "exercisedValue": 0, "unexercisedValue": 41527968}, {"maxAge": 1, "name": "Ms. Seline E. Miller CPA", "age": 54, "title": "Senior Vice President of Finance", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 11.29, "open": 11.23, "dayLow": 11.1601, "dayHigh": 11.6, "regularMarketPreviousClose": 11.29, "regularMarketOpen": 11.23, "regularMarketDayLow": 11.1601, "regularMarketDayHigh": 11.6, "payoutRatio": 0.0, "forwardPE": 25.217392, "volume": 37272, "regularMarketVolume": 37272, "averageVolume": 102738, "averageVolume10days": 55830, "averageDailyVolume10Day": 55830, "bid": 11.42, "ask": 11.69, "bidSize": 1, "askSize": 1, "marketCap": 995538752, "fiftyTwoWeekLow": 8.26, "fiftyTwoWeekHigh": 22.0, "priceToSalesTrailing12Months": 9.478343, "fiftyDayAverage": 11.3554, "twoHundredDayAverage": 12.3896, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1007536384, "profitMargins": -0.84566003, "floatShares": 16118281, "sharesOutstanding": 85822304, "sharesShort": 1254517, "sharesShortPriorMonth": 1262551, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.0146, "heldPercentInsiders": 0.74626, "heldPercentInstitutions": 0.01958, "shortRatio": 21.22, "shortPercentOfFloat": 0.1866, "impliedSharesOutstanding": 85822304, "bookValue": 0.737, "priceToBook": 15.739485, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.717, "netIncomeToCommon": -88822000, "trailingEps": -1.04, "forwardEps": 0.46, "lastSplitFactor": "1:15", "lastSplitDate": 1698710400, "enterpriseToRevenue": 9.593, "enterpriseToEbitda": 85.37, "52WeekChange": -0.4761021, "SandP52WeekChange": 0.14239466, "lastDividendValue": 3.6, "lastDividendDate": 1673568000, "quoteType": "EQUITY", "currentPrice": 11.6, "recommendationKey": "none", "totalCash": 25092000, "totalCashPerShare": 0.292, "ebitda": 11802000, "totalDebt": 1795000, "quickRatio": 3.111, "currentRatio": 3.724, "totalRevenue": 105033000, "debtToEquity": 1.823, "revenuePerShare": 1.285, "returnOnEquity": -0.85323995, "grossProfits": 101076000, "operatingCashflow": 2477000, "earningsGrowth": -0.738, "revenueGrowth": -0.205, "grossMargins": 0.96233004, "ebitdaMargins": 0.11236, "operatingMargins": 0.16608, "financialCurrency": "USD", "symbol": "GYRE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Gyre Therapeutics, Inc.", "postMarketTime": 1740777406, "regularMarketTime": 1740776402, "messageBoardId": "finmb_100542295", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Gyre Therapeutics, Inc.", "regularMarketChangePercent": 2.7457964, "regularMarketPrice": 11.6, "exchange": "NCM", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1144848600000, "postMarketChangePercent": 0.0, "postMarketPrice": 11.6, "postMarketChange": 0.0, "regularMarketChange": 0.31000042, "regularMarketDayRange": "11.1601 - 11.6", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 102738, "fiftyTwoWeekLowChange": 3.3400002, "fiftyTwoWeekLowChangePercent": 0.40435836, "fiftyTwoWeekRange": "8.26 - 22.0", "fiftyTwoWeekHighChange": -10.4, "fiftyTwoWeekHighChangePercent": -0.47272727, "fiftyTwoWeekChangePercent": -47.61021, "dividendDate": 1673481600, "earningsTimestamp": 1739885400, "earningsTimestampStart": 1742819400, "earningsTimestampEnd": 1743165000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.04, "epsForward": 0.46, "fiftyDayAverageChange": 0.2446003, "fiftyDayAverageChangePercent": 0.021540439, "twoHundredDayAverageChange": -0.7895994, "twoHundredDayAverageChangePercent": -0.06373083, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "corporateActions": [], "cryptoTradeable": false, "displayName": "Gyre Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]